Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
Hebron University · Vall d'Hebron Institut de Recerca · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
248
total citations
- FWCI
- 53.84
- Percentile
- 100%
- References
- 27
Citations per year
Authors
16- EFEnriqueta FelipCorresponding
Hebron University, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
- NKNasser K. Altorki
NewYork–Presbyterian Hospital, Cornell University, New York Hospital Queens, Presbyterian Hospital, Weill Cornell Medicine
- CZCaicun Zhou
Tongji University, Shanghai Pulmonary Hospital
- EVEric Vallières
Swedish Medical Center, Seattle University
- AMAlex Martínez‐Martí
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
Topics & keywords
Topics
Keywords
- Medicine
- Atezolizumab
- Hazard ratio
- Interim analysis
- Internal medicine
- Population
- Clinical endpoint
- Lung cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.